On Friday, Agios Pharmaceuticals Inc (NASDAQ: AGIO) was -4.71% drop from the session before settling in for the closing price of $33.98. A 52-week range for AGIO has been $27.14 – $62.58.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 4.89% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -164.05%. With a float of $55.16 million, this company’s outstanding shares have now reached $57.16 million.
In an organization with 488 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 80.53%, operating margin of -1166.47%, and the pretax margin is 1967.15%.
Agios Pharmaceuticals Inc (AGIO) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Agios Pharmaceuticals Inc stocks. The insider ownership of Agios Pharmaceuticals Inc is 3.64%, while institutional ownership is 106.79%. The most recent insider transaction that took place on Mar 03 ’25, was worth 142,338. In this transaction Chief Legal Officer of this company sold 4,005 shares at a rate of $35.54, taking the stock ownership to the 18,650 shares. Before that another transaction happened on Mar 03 ’25, when Company’s Chief Financial Officer sold 2,275 for $35.54, making the entire transaction worth $80,854. This insider now owns 21,843 shares in total.
Agios Pharmaceuticals Inc (AGIO) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.85 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -164.05% per share during the next fiscal year.
Agios Pharmaceuticals Inc (NASDAQ: AGIO) Trading Performance Indicators
You can see what Agios Pharmaceuticals Inc (AGIO) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 11.56. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 50.83.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 11.40, a number that is poised to hit -1.78 in the next quarter and is forecasted to reach -6.27 in one year’s time.
Technical Analysis of Agios Pharmaceuticals Inc (AGIO)
Let’s dig in a bit further. During the last 5-days, its volume was 0.69 million. That was inferior than the volume of 0.76 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 27.47%. Additionally, its Average True Range was 1.58.
During the past 100 days, Agios Pharmaceuticals Inc’s (AGIO) raw stochastic average was set at 3.19%, which indicates a significant increase from 1.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 45.53% in the past 14 days, which was lower than the 65.77% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $33.85, while its 200-day Moving Average is $42.90. However, in the short run, Agios Pharmaceuticals Inc’s stock first resistance to watch stands at $33.79. Second resistance stands at $35.21. The third major resistance level sits at $35.94. If the price goes on to break the first support level at $31.64, it is likely to go to the next support level at $30.91. Assuming the price breaks the second support level, the third support level stands at $29.49.
Agios Pharmaceuticals Inc (NASDAQ: AGIO) Key Stats
There are 57,296K outstanding shares of the company, which has a market capitalization of 1.86 billion. As of now, sales total 36,500 K while income totals 673,730 K. Its latest quarter income was 10,730 K while its last quarter net income were -96,520 K.
